EP1004673B1 - Process for producing foreign proteins - Google Patents

Process for producing foreign proteins Download PDF

Info

Publication number
EP1004673B1
EP1004673B1 EP98911202A EP98911202A EP1004673B1 EP 1004673 B1 EP1004673 B1 EP 1004673B1 EP 98911202 A EP98911202 A EP 98911202A EP 98911202 A EP98911202 A EP 98911202A EP 1004673 B1 EP1004673 B1 EP 1004673B1
Authority
EP
European Patent Office
Prior art keywords
medium
hsa
culture
foreign proteins
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP98911202A
Other languages
German (de)
French (fr)
Other versions
EP1004673A4 (en
EP1004673A1 (en
Inventor
Toyoo Yoshitomi Pharmaceutical Ind. Ltd OHDA
Tomoshi Yoshitomi Pharmaceutical Ind. Ltd. OHYA
Shinobu Yoshitomi Pharmaceutical Ind. Ltd KUWAE
Masao Yoshitomi Pharmaceutical Ind. Ltd OHYAMA
Kaoru Yoshitomi Pharmaceutical Ind. Ltd KOBAYASHI
Yahiro Uemura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of EP1004673A1 publication Critical patent/EP1004673A1/en
Publication of EP1004673A4 publication Critical patent/EP1004673A4/en
Application granted granted Critical
Publication of EP1004673B1 publication Critical patent/EP1004673B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Definitions

  • the present invention relates to an improvement in the method for production of HSA (human serum albumin) comprising culturing a yeast transformed by gene manipulation.
  • HSA human serum albumin
  • HSA human serum albumin
  • EP-A-0 470 575 discloses an improved process for producing esterase which comprises cultivating an esterase producing microorganism in a medium.
  • WO 90 03430 A discloses improved media for the cultivation of animal cells and the production of natural and recombinant products derived therefrom.
  • US-A-5 024 947 discloses media supporting the growth of insect cells and the production thereby of recombinant proteins.
  • the present invention aims at increasing the production amount of HSA by particularly improving culture conditions.
  • the present inventors have conducted intensive studies in an attempt to solve the above-mentioned problems, and found that the production amount of a HSA can be increased by culturing a yeast prepared by gene manipulation in a medium containing a fatty acid or a salt thereof, and a surfactant, which resulted in the completion of the present invention. Accordingly, the present invention provides the following.
  • the host is a yeast, which may be the genus Saccharomyces or the genus Pichia .
  • Auxotrophic strain and antibiotic sensitive strain of these hosts can be also used.
  • Sacccharomyces cerevisiae AH22 strain which is a G418 sensitive strain (a, his 4, leu 2, can 1)
  • Pichia pastoris GTS115 strain his 4, NRRL deposit No. Y-15851
  • an HSA-producing host (or an HSA-producing strain) can be prepared by a method using a known HSA gene (JP-A-58-56684, JP-A-58-90515, JP-A-58-150517), a method using a novel HSA gene (JP-A-62-29985, JP-A-1-98486), a method using a synthetic signal sequence (JP-A-1-240191), a method using a serum albumin signal sequence (JP-A-2-167095), a method comprising integration of a recombinant plasmid on a chromosome (JP-A-3-72889), a method comprising fusion of hosts (JP-A-3-53877), a method comprising mutation in a medium containing methanol, a method using a mutant AOX2 promoter (JP-A-6-90768, JP-A-4-299984), expression of HSA by Bacillus subtilis (JP-A-62-25133), expression
  • the method causing mutation in a medium containing methanol is performed as follows.
  • a plasmid having a transcription unit to express HSA under the control of AOX1 promoter is introduced into the AOX1 gene region of a suitable host, preferably Pichia yeast, specifically Pichia pastoris GTS115 strain by a conventional method to give a transformant (see JP-A-2-104290).
  • This transformant has a weak proliferation capability in a medium containing methanol.
  • this transformant is cultured in a medium containing methanol to cause mutation and only the strain capable of growth is recovered.
  • the concentration of methanol is approximately 0.0001% - 5%.
  • the medium may be synthetic or natural.
  • the culture conditions are 15°C - 40°C, 1 hour - 1000 hours.
  • the medium to be used for culturing a transformed host contains a fatty acid or a salt thereof, and a surfactant, it is subject to no particular limitation with regard to other components, and a medium known in this field is usually used. Culturing of a transformed host in a medium containing a fatty acid or a salt thereof, and a surfactant enables increase in the production amount of a heterologous protein.
  • the enzyme that the host itself secretes is expected to suppress decomposition of the heterologous protein.
  • Examples of fatty add preferably include those having 10 to 26 carbon atoms.
  • fatty acid examples include saturated and unsaturated fatty acids such as myristic acid, palmitic acid, palmitoleic acid, oleic acid, t-vaccenic acid, linoleic acid, linolenic acid, linoleic acid, and arachidonic acid.
  • the salts of these fatty acids are, for example, alkali metal salt such as sodium salt, potassium salt, and calcium salt, alkaline earth metal salts and organic amine salts, with preference given to a medium containing oleic acid or a salt thereof.
  • the content of fatty acid in the medium is 0.01 - 10 W/V%, preferably 0.2 - 5 W/V%.
  • the surfactant to be used in the present invention is a non-ionic surfactant preferably having a high molecular weight of from 100 to 100,000.
  • non-ionic surfactant examples include polyalkylene glycol (e.g., polypropylene glycol having an average molecular weight of 1000 - 10,000, preferably 2,000 - 6,000), polyoxy-alkylene copolymer (e.g., polyoxyethylene-polyoxypropylene copolymer having an average molecular weight of 100 - 100,000, preferably 1,000 - 30,000), hydrogenated castor oil polyoxyalkylene derivative [e.g., hydrogenated castor oil polyoxyethylene(20)-ether, hydrogenated castor oil polyoxyethylene-(40)-ether, hydrogenated castor oil polyoxyethylene-(100)-ether], castor oil polyoxyalkylene derivative[e.g., castor oil polyoxyethylene(20)-ether, castor oil polyoxyethylene-(40)-ether, castor oil polyoxyetliylene-(100)-ether], polyoxyethylenesorbitan fatty acid ester (e.g., polyoxyethylenesorbitan monooleate, polyoxyethylene
  • the content of the surfactant in a medium is preferably not more than 0.5 g/ L.
  • the medium may be a synthetic medium or a natural medium, with preference given to a synthetic medium. It may be a solid medium or liquid medium, preferably a liquid medium.
  • a synthetic medium generally contains various saccharides as a carbon source, urea, ammonium salt, and nitrate as a nitrogen source, various vitamins, and nucleotide as trace nutrients and inorganic salts (e.g., Mg, Ca, Fe, Na, K, Mn, Co, Cu and the like).
  • examples of the medium include a YNB liquid medium [0.7% yeast nitrogen base (manufactured by Difco), 2% glucose].
  • the natural medium examples include a YPD liquid medium [1% yeast extract (manufactured by Difco), 2% bactopeptone (manufactured by Difco), 2% glucose].
  • a medium containing methanol can be used. In this case, the concentration of methanol is preferably about 0.01 - 5%.
  • the medium used in the present invention can be prepared easily by adding a fatty acid or a salt thereof, and a surfactant to a conventionally known medium.
  • the culture temperature is, for example, 15°C - 40°C, generally 20°C - 37°C.
  • the host is a yeast, it is preferably 20°C - 30°C, and when the host is bacteria, it is preferably 30°C - 37°C.
  • the culture time is generally 1 hour - 1000 hours.
  • the culturing is performed by batch culture or fed batch culture or continuous culture with standing still or shaking, stirring or aeration, preferably fed batch using a fermenter.
  • high concentration glucose is added in portions to fed batch culture, avoiding high concentration substrate inhibition relative to producing cells, whereby high concentration cells and products are obtained (JP-A-3-83595).
  • the medium for pre-culture may be, for example, YNB liquid medium or YPD liquid medium.
  • the conditions of pre-culture are preferably culture time of 10 hours - 100 hours, temperature of about 30°C for yeasts, and about 37°C for bacteria.
  • a HSA is harvested by a known method of separation and purification from the culture.
  • the culture covers any substance capable of containing HSA, such as a culture medium, and a yeast which is specifically a culture supernatant, a filtrate thereof, a bacterial cell, and a cell.
  • AOX2 promoter [natural AOX2 promoter (YEAST, 5, 167-177 (1988) or Mol. Cell Biol, 9, 1316-1323 (1989)) wherein 255 th nucleotide upstream of initiation codon was changed from T to C]
  • a plasmid pMM042 for HSA expression was constructed and introduced into Pichia pastoris GTS115 strain to give a transformant UHG42-3 strain (JP-A-4-29984).
  • YPD medium 2% bactopeptone, 1% yeast extract, 2% glucose
  • the composition of batch medium used for main culture is shown in Table 1, and the composition of feed medium is shown in Table 2.
  • the composition of the solution of *2 in Table 1 and Table 2 is shown in Table 3.
  • the oleic acid content of the batch medium and feed medium used in this Example was set to 0.5 W/V%.
  • composition of batch medium Component Amount (1/L) Glycerol 50.0 g H 3 PO 4 (85%) 14.0 ml CaSO 4 ⁇ 2H 2 O 0.6 g K 2 SO 4 9.5 g MgSO 4 ⁇ 7H 2 O 7.8 g KOH 2.6 g Biotin solution () 1.6 ml YTM solution () 4.4 ml Oleic acid 5.0 g
  • Composition of feed medium Component Amount (1/L) YTM solution () 2.0 ml Oleic acid 5.0 g Methanol 1000.0 ml
  • Composition of YTM solution Component Amount (1/L) FeSO 4 ⁇ 7H 2 O 65.0 g CuSO 4 ⁇ 5H 2 O 6.0 g ZnSO 4 ⁇ 7H 2 O 20.0 g MnSO 4 ⁇ 4-5H 2 O 3.0 g H 2 SO 4 5.0 ml
  • a bacterial cell suspension (1 ml, about OD 540 ⁇ about 10) was inoculated to YPD medium (50 ml) and subjected to shake culture at 30°C for 24 hours.
  • the pre-culture (14 ml) was inoculated to batch medium (700 ml) and subjected to aeration stirring culture in a mini-jar fermenter.
  • the culture temperature was 25°C
  • pH was 5.8.
  • Adekanol LG-109 manufactured by Asahi Denka Kogyo, which is a polyoxyalkylene surfactant, was added to the medium to a concentration of 0.4 g/L.
  • the culture was sampled and the amount of HSA production was measured by the method described in the following examples. As a result, the amount was 114% when the production without oleic acid addition was 100%.
  • Example 2 In the same manner as in Example 1 except that the oleic acid concentration of the feed medium was set to 1 W/V%, culturing was performed. The amount of HSA production was 125%.
  • Example 2 In the same manner as in Example 1 except that the oleic acid concentration of the feed medium was set to 5 W/V%, culturing was performed. The amount of HSA production was 127%.
  • the amount of HSA produced by a yeast can be increased and decomposition of HSA by an enzyme secreted by the yeast itself can be inhibited, whereby the amount of HSA harvested can be increased.
  • the present invention comprises culturing of a HSA yeast in a medium containing a fatty acid or a salt thereof, and a surfactant, and is an easy and simple method.

Abstract

A process for producing foreign proteins characterized by culturing foreign protein-producing hosts constructed by gene manipulation in media containing fatty acids or salts thereof and surfactants and harvesting the foreign proteins from the cultures. Thus the yields of the foreign proteins produced by the hosts can be elevated. Moreover, the degradation of the foreign proteins by enzymes originating in the hosts can be thus inhibited, which enables mass production of the foreign proteins.

Description

Technical Field
The present invention relates to an improvement in the method for production of HSA (human serum albumin) comprising culturing a yeast transformed by gene manipulation.
Background Art
While a broad range of proteins useful as pharmaceuticals, such as human serum albumin (hereinafter to be referred to as HSA), which is a major protein component of plasma, and the like are produced by fractionation of body fluid, this method is confronted with difficulty in securing the starting material, and the produced preparations have a strong possibility of contamination with virus and the like. The advent of the recombinant DNA technology in recent years has enabled production of such proteins by microorganisms and cells, which encourages study and development of large scale production of heterologous protein by genetic engineering. However, the yield is still low and a large scale production has not been attainable.
The method for increasing the production of heterologous protein includes a method comprising adding a fatty acid or a salt thereof to a medium to increase production of recombinant HSA (hereinafter to be referred to as rHSA) (JP-A-4-293495), a method comprising adding a high concentration surfactant having a polyalkylene glycol group (Japanese Patent Application under PCT laid-open under kohyo No. 3-500969 = WO 90/02808).
EP-A-0 470 575 discloses an improved process for producing esterase which comprises cultivating an esterase producing microorganism in a medium. WO 90 03430 A discloses improved media for the cultivation of animal cells and the production of natural and recombinant products derived therefrom. US-A-5 024 947 discloses media supporting the growth of insect cells and the production thereby of recombinant proteins.
In view of such technical background, the present invention aims at increasing the production amount of HSA by particularly improving culture conditions.
Disclosure of the Invention
The present inventors have conducted intensive studies in an attempt to solve the above-mentioned problems, and found that the production amount of a HSA can be increased by culturing a yeast prepared by gene manipulation in a medium containing a fatty acid or a salt thereof, and a surfactant, which resulted in the completion of the present invention.
Accordingly, the present invention provides the following.
  • (1) A production method of HSA (human serum albumin), comprising culturing a yeast prepared by gene manipulation in a medium containing a fatty acid or a salt thereof, and a surfactantat a concentration of not more than 0.5 g/L, and harvesting HSA from the culture.
  • (2) The production method of (1) above, wherein the fatty acid has 10 to 26 carbon atoms.
  • (3) The production method of (1) above, wherein the medium contains a fatty acid or a salt thereof at a concentration of 0.01 - 10 W/V%.
  • (4) The production method of (1) above, wherein the surfactant is a non-ionic surfactant having a molecular weight of 100-100,000.
    • In the present invention, the host is a yeast, which may be the genus Saccharomyces or the genus Pichia. Auxotrophic strain and antibiotic sensitive strain of these hosts can be also used. Preferably, Sacccharomyces cerevisiae AH22 strain which is a G418 sensitive strain (a, his 4, leu 2, can 1), and Pichia pastoris GTS115 strain (his 4, NRRL deposit No. Y-15851) can be used.
    For example, an HSA-producing host (or an HSA-producing strain) can be prepared by a method using a known HSA gene (JP-A-58-56684, JP-A-58-90515, JP-A-58-150517), a method using a novel HSA gene (JP-A-62-29985, JP-A-1-98486), a method using a synthetic signal sequence (JP-A-1-240191), a method using a serum albumin signal sequence (JP-A-2-167095), a method comprising integration of a recombinant plasmid on a chromosome (JP-A-3-72889), a method comprising fusion of hosts (JP-A-3-53877), a method comprising mutation in a medium containing methanol, a method using a mutant AOX2 promoter (JP-A-6-90768, JP-A-4-299984), expression of HSA by Bacillus subtilis (JP-A-62-25133), expression of HSA by yeast (JP-A-60-41487, JP-A-63-39576, JP-A-63-74493), expression of HSA by Pichia yeast (JP-A-2-104290).
    Of these, the method causing mutation in a medium containing methanol is performed as follows. A plasmid having a transcription unit to express HSA under the control of AOX1 promoter is introduced into the AOX1 gene region of a suitable host, preferably Pichia yeast, specifically Pichia pastoris GTS115 strain by a conventional method to give a transformant (see JP-A-2-104290). This transformant has a weak proliferation capability in a medium containing methanol. Thus, according to the method disclosed in JP-A-4-299984, this transformant is cultured in a medium containing methanol to cause mutation and only the strain capable of growth is recovered. In this case, the concentration of methanol is approximately 0.0001% - 5%. The medium may be synthetic or natural. The culture conditions are 15°C - 40°C, 1 hour - 1000 hours.
    As long as the medium to be used for culturing a transformed host contains a fatty acid or a salt thereof, and a surfactant, it is subject to no particular limitation with regard to other components, and a medium known in this field is usually used. Culturing of a transformed host in a medium containing a fatty acid or a salt thereof, and a surfactant enables increase in the production amount of a heterologous protein. In addition, the enzyme that the host itself secretes is expected to suppress decomposition of the heterologous protein.
    Examples of fatty add preferably include those having 10 to 26 carbon atoms.
    Examples of the aforementioned fatty acid include saturated and unsaturated fatty acids such as myristic acid, palmitic acid, palmitoleic acid, oleic acid, t-vaccenic acid, linoleic acid, linolenic acid, linoleic acid, and arachidonic acid. The salts of these fatty acids are, for example, alkali metal salt such as sodium salt, potassium salt, and calcium salt, alkaline earth metal salts and organic amine salts, with preference given to a medium containing oleic acid or a salt thereof.
    The content of fatty acid in the medium is 0.01 - 10 W/V%, preferably 0.2 - 5 W/V%.
    The surfactant to be used in the present invention is a non-ionic surfactant preferably having a high molecular weight of from 100 to 100,000.
    Examples of the aforementioned non-ionic surfactant include polyalkylene glycol (e.g., polypropylene glycol having an average molecular weight of 1000 - 10,000, preferably 2,000 - 6,000), polyoxy-alkylene copolymer (e.g., polyoxyethylene-polyoxypropylene copolymer having an average molecular weight of 100 - 100,000, preferably 1,000 - 30,000), hydrogenated castor oil polyoxyalkylene derivative [e.g., hydrogenated castor oil polyoxyethylene(20)-ether, hydrogenated castor oil polyoxyethylene-(40)-ether, hydrogenated castor oil polyoxyethylene-(100)-ether], castor oil polyoxyalkylene derivative[e.g., castor oil polyoxyethylene(20)-ether, castor oil polyoxyethylene-(40)-ether, castor oil polyoxyetliylene-(100)-ether], polyoxyethylenesorbitan fatty acid ester (e.g., polyoxyethylenesorbitan monooleate, polyoxyethylenesorbitan monostearate, polyoxyethylenesorbitan monopalmitate, polyoxyethylenesorbitan monolaurate), sorbitan fatty acid ester, alkylphenolpolyoxyethylene ether, polyoxyethylenesorbit fatty acid ester, polyoxyethylene hydrogenated castor oil, and polyglycerine fatty acid ester. In particular, it is preferable that the medium should contain polyalkylene glycol, polyoxyethylenepolyoxypropylene copolymer (trademark Pluronic), or polyoxyethylenesorbitan fatty acid ester (trademark Tween).
    The content of the surfactant in a medium is preferably not more than 0.5 g/ L.
    The medium may be a synthetic medium or a natural medium, with preference given to a synthetic medium. It may be a solid medium or liquid medium, preferably a liquid medium. For example, a synthetic medium generally contains various saccharides as a carbon source, urea, ammonium salt, and nitrate as a nitrogen source, various vitamins, and nucleotide as trace nutrients and inorganic salts (e.g., Mg, Ca, Fe, Na, K, Mn, Co, Cu and the like). Examples of the medium include a YNB liquid medium [0.7% yeast nitrogen base (manufactured by Difco), 2% glucose]. Examples of the natural medium include a YPD liquid medium [1% yeast extract (manufactured by Difco), 2% bactopeptone (manufactured by Difco), 2% glucose]. When a methanol utilizing host is used, a medium containing methanol can be used. In this case, the concentration of methanol is preferably about 0.01 - 5%.
    The medium used in the present invention can be prepared easily by adding a fatty acid or a salt thereof, and a surfactant to a conventionally known medium.
    Other conditions for culturing are similar to those used for a conventional method.
    The culture temperature is, for example, 15°C - 40°C, generally 20°C - 37°C. When the host is a yeast, it is preferably 20°C - 30°C, and when the host is bacteria, it is preferably 30°C - 37°C. The culture time is generally 1 hour - 1000 hours.
    The culturing is performed by batch culture or fed batch culture or continuous culture with standing still or shaking, stirring or aeration, preferably fed batch using a fermenter. For example, high concentration glucose is added in portions to fed batch culture, avoiding high concentration substrate inhibition relative to producing cells, whereby high concentration cells and products are obtained (JP-A-3-83595).
    It is preferable that a pre-culture should be performed before this culturing. The medium for pre-culture may be, for example, YNB liquid medium or YPD liquid medium. The conditions of pre-culture are preferably culture time of 10 hours - 100 hours, temperature of about 30°C for yeasts, and about 37°C for bacteria.
    After the completion of the culturing, a HSA is harvested by a known method of separation and purification from the culture. As used herein, the culture covers any substance capable of containing HSA, such as a culture medium, and a yeast which is specifically a culture supernatant, a filtrate thereof, a bacterial cell, and a cell.
    The present invention is explained in detail in the following by way of Example and Experimental Example, to which the present invention is not limited.
    Example 1 (1) Preparation of bacterial strain used
    Using a mutant AOX2 promoter [natural AOX2 promoter (YEAST, 5, 167-177 (1988) or Mol. Cell Biol, 9, 1316-1323 (1989)) wherein 255th nucleotide upstream of initiation codon was changed from T to C], a plasmid pMM042 for HSA expression was constructed and introduced into Pichia pastoris GTS115 strain to give a transformant UHG42-3 strain (JP-A-4-29984).
    (2) Composition of medium
    For pre-culture, YPD medium (2% bactopeptone, 1% yeast extract, 2% glucose) was used. The composition of batch medium used for main culture is shown in Table 1, and the composition of feed medium is shown in Table 2. The composition of the solution of *2 in Table 1 and Table 2 is shown in Table 3. As shown in Table 1 and Table 2, the oleic acid content of the batch medium and feed medium used in this Example was set to 0.5 W/V%.
    Composition of batch medium
    Component Amount (1/L)
    Glycerol 50.0 g
    H3PO4 (85%) 14.0 ml
    CaSO4·2H2O 0.6 g
    K2SO4 9.5 g
    MgSO4·7H2O 7.8 g
    KOH 2.6 g
    Biotin solution () 1.6 ml
    YTM solution () 4.4 ml
    Oleic acid 5.0 g
    Composition of feed medium
    Component Amount (1/L)
    YTM solution () 2.0 ml
    Oleic acid 5.0 g
    Methanol 1000.0 ml
    Composition of YTM solution
    Component Amount (1/L)
    FeSO4·7H2O 65.0 g
    CuSO4·5H2O 6.0 g
    ZnSO4·7H2O 20.0 g
    MnSO4·4-5H2O 3.0 g
    H2SO4 5.0 ml
    (3) Culture method using fermenter 1 ○ Pre-culture
    A bacterial cell suspension (1 ml, about OD540 ≒ about 10) was inoculated to YPD medium (50 ml) and subjected to shake culture at 30°C for 24 hours.
    2 ○ Main culture
    The pre-culture (14 ml) was inoculated to batch medium (700 ml) and subjected to aeration stirring culture in a mini-jar fermenter. The culture temperature was 25°C, pH was 5.8. Adekanol LG-109 (manufactured by Asahi Denka Kogyo), which is a polyoxyalkylene surfactant, was added to the medium to a concentration of 0.4 g/L.
    In batch culture, when the yeast proliferated to a sufficiently high density and glycerol in the medium was consumed, feed medium was added and cultured for 360 hours to allow production of HSA
    After the completion of the culturing, the culture was sampled and the amount of HSA production was measured by the method described in the following examples. As a result, the amount was 114% when the production without oleic acid addition was 100%.
    Example 2
    In the same manner as in Example 1 except that the oleic acid concentration of the feed medium was set to 1 W/V%, culturing was performed. The amount of HSA production was 125%.
    Example 3
    In the same manner as in Example 1 except that the oleic acid concentration of the feed medium was set to 5 W/V%, culturing was performed. The amount of HSA production was 127%.
    Example 4
    In the same manner as in Example 1 except that the surfactant in the feed medium was Pluronic L-61 (average molecular weight 2,000, ethylene oxide:propylene oxide=10:90, manufactured by Asahi Denka Kogyo), which is a polyoxyethylene-polyoxypropylene copolymer, culturing was performed.
    Reference Example Quantitative determination of HSA concentration
    A part of the recovered culture was centrifuged and the supernatant was filtered after it became clear, which was followed by quantitative determination by gel filtration analysis by HPLC.
    According to the present invention, the amount of HSA produced by a yeast can be increased and decomposition of HSA by an enzyme secreted by the yeast itself can be inhibited, whereby the amount of HSA harvested can be increased. The present invention comprises culturing of a HSA yeast in a medium containing a fatty acid or a salt thereof, and a surfactant, and is an easy and simple method.

    Claims (4)

    1. A production method of HSA (human serum albumin), comprising culturing a yeast prepared by gene manipulation in a medium containing a fatty acid or a salt thereof, and a surfactant at a concentration of not more than 0.5 g/L, and harvesting HSA from the culture.
    2. The production method of claim 1, wherein the fatty acid has 10 to 26 carbon atoms.
    3. The production method of claim 1, wherein the medium contains a fatty acid or a salt thereof at a concentration of 0.01 - 10 W / V %.
    4. The production method of claim 1, wherein the surfactant is a non-ionic surfactant having a molecular weight of 100 - 100,000.
    EP98911202A 1997-04-03 1998-04-03 Process for producing foreign proteins Expired - Lifetime EP1004673B1 (en)

    Applications Claiming Priority (3)

    Application Number Priority Date Filing Date Title
    JP8506497 1997-04-03
    JP8506497 1997-04-03
    PCT/JP1998/001552 WO1998044146A1 (en) 1997-04-03 1998-04-03 Process for producing foreign proteins

    Publications (3)

    Publication Number Publication Date
    EP1004673A1 EP1004673A1 (en) 2000-05-31
    EP1004673A4 EP1004673A4 (en) 2003-01-15
    EP1004673B1 true EP1004673B1 (en) 2005-12-07

    Family

    ID=13848211

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP98911202A Expired - Lifetime EP1004673B1 (en) 1997-04-03 1998-04-03 Process for producing foreign proteins

    Country Status (13)

    Country Link
    US (1) US6309864B1 (en)
    EP (1) EP1004673B1 (en)
    KR (1) KR100389729B1 (en)
    CN (1) CN1257549A (en)
    AT (1) ATE312195T1 (en)
    AU (1) AU746670B2 (en)
    BR (1) BR9808472A (en)
    CA (1) CA2286395C (en)
    DE (1) DE69832709T2 (en)
    ES (1) ES2255154T3 (en)
    NO (1) NO994788L (en)
    PL (1) PL335975A1 (en)
    WO (1) WO1998044146A1 (en)

    Families Citing this family (4)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    WO2001027275A1 (en) * 1999-10-13 2001-04-19 Lexicon Genetics Incorporated Novel human membrane proteins
    JP6909591B2 (en) * 2017-03-01 2021-07-28 三洋化成工業株式会社 Production method of useful substances
    JP2018143238A (en) * 2017-03-01 2018-09-20 三洋化成工業株式会社 Method for producing useful material
    JP7141227B2 (en) 2018-03-27 2022-09-22 三洋化成工業株式会社 Method for producing useful substances

    Family Cites Families (9)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    JPS60196185A (en) * 1984-03-19 1985-10-04 Chemo Sero Therapeut Res Inst Cultivation of transformed yeast
    US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
    DE3851685D1 (en) * 1987-10-13 1994-11-03 Thomae Gmbh Dr K Process for the production of proteins.
    GB8820951D0 (en) * 1988-09-07 1988-10-05 Delta Biotechnology Ltd Fermentation method
    DE68925971T2 (en) * 1988-09-23 1996-09-05 Cetus Oncology Corp CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
    US5378612A (en) * 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
    JPH0714342B2 (en) * 1990-08-10 1995-02-22 田辺製薬株式会社 Esterase manufacturing method
    JPH0671432B2 (en) 1991-03-20 1994-09-14 株式会社ミドリ十字 Method for producing human serum albumin
    JPH0823995A (en) * 1994-07-14 1996-01-30 Green Cross Corp:The Production of protein degradable by protease derived from host cell

    Also Published As

    Publication number Publication date
    AU6522898A (en) 1998-10-22
    CN1257549A (en) 2000-06-21
    NO994788L (en) 1999-12-02
    ES2255154T3 (en) 2006-06-16
    EP1004673A4 (en) 2003-01-15
    ATE312195T1 (en) 2005-12-15
    DE69832709D1 (en) 2006-01-12
    CA2286395A1 (en) 1998-10-08
    AU746670B2 (en) 2002-05-02
    BR9808472A (en) 2000-05-23
    KR100389729B1 (en) 2003-07-02
    NO994788D0 (en) 1999-10-01
    US6309864B1 (en) 2001-10-30
    WO1998044146A1 (en) 1998-10-08
    EP1004673A1 (en) 2000-05-31
    DE69832709T2 (en) 2006-07-06
    KR20010005979A (en) 2001-01-15
    CA2286395C (en) 2009-06-23
    PL335975A1 (en) 2000-06-05

    Similar Documents

    Publication Publication Date Title
    Cregg et al. Recent advances in the expression of foreign genes in Pichia pastoris
    JP3579430B2 (en) Expression of human serum albumin in Pichia pastoris
    EP0156355B2 (en) Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
    US5334512A (en) Fatty acid supplemented medium for recombinant production of human serum albumin by yeast
    EP1004673B1 (en) Process for producing foreign proteins
    KR100404273B1 (en) Method of producing recombinant human serum albumin
    US5260202A (en) Fermentation method
    CA2136564C (en) Process for producing human serum albumin
    EP0362183A2 (en) Process for the production of human lysozyme
    JP2996405B2 (en) Fermentation method
    US20030059925A1 (en) Fermentation medium and method
    JP3837775B2 (en) Method for inhibiting degradation of human serum albumin
    JP3772355B2 (en) Method for producing human serum albumin
    KR0177321B1 (en) Mass production method of human alpha interferon from recombinant yeast
    KR100241266B1 (en) Process for improving productivity of human alpha-iterferon from recombinant yeast
    JPH1014564A (en) Production of protein
    JP2005312463A (en) Method for producing human serum albumin
    CN101928721B (en) Preparation of new apolipoprotein C-I

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    17P Request for examination filed

    Effective date: 19991026

    AK Designated contracting states

    Kind code of ref document: A1

    Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    RAP1 Party data changed (applicant data changed or rights of an application transferred)

    Owner name: WELFIDE CORPORATION

    RAP1 Party data changed (applicant data changed or rights of an application transferred)

    Owner name: MITSUBISHI PHARMA CORPORATION

    A4 Supplementary search report drawn up and despatched

    Effective date: 20021203

    AK Designated contracting states

    Kind code of ref document: A4

    Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    RIN1 Information on inventor provided before grant (corrected)

    Inventor name: UEMURA, YAHIRO

    Inventor name: KOBAYASHI, KAORUYOSHITOMI PHARMACEUTICAL IND. LTD

    Inventor name: OHYAMA, MASAOYOSHITOMI PHARMACEUTICAL IND. LTD

    Inventor name: KUWAE,SHINOBUYOSHITOMI PHARMACEUTICAL IND. LTD

    Inventor name: OHYA, TOMOSHIYOSHITOMI PHARMACEUTICAL IND. LTD.

    Inventor name: OHDA, TOYOOYOSHITOMI PHARMACEUTICAL IND. LTD

    17Q First examination report despatched

    Effective date: 20030716

    GRAP Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOSNIGR1

    GRAS Grant fee paid

    Free format text: ORIGINAL CODE: EPIDOSNIGR3

    GRAA (expected) grant

    Free format text: ORIGINAL CODE: 0009210

    AK Designated contracting states

    Kind code of ref document: B1

    Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: FI

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20051207

    Ref country code: AT

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20051207

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: FG4D

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: EP

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: FG4D

    REF Corresponds to:

    Ref document number: 69832709

    Country of ref document: DE

    Date of ref document: 20060112

    Kind code of ref document: P

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: NV

    Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: SE

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20060307

    Ref country code: GR

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20060307

    Ref country code: DK

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20060307

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: IE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20060403

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: MC

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20060430

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: PT

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20060508

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FG2A

    Ref document number: 2255154

    Country of ref document: ES

    Kind code of ref document: T3

    ET Fr: translation filed
    PLBE No opposition filed within time limit

    Free format text: ORIGINAL CODE: 0009261

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

    26N No opposition filed

    Effective date: 20060908

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: MM4A

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PFA

    Owner name: MITSUBISHI PHARMA CORPORATION

    Free format text: MITSUBISHI PHARMA CORPORATION#6-9, HIRANOMACHI 2-CHOME, CHUO-KU#OSAKA-SHI, OSAKA 541-0046 (JP) -TRANSFER TO- MITSUBISHI PHARMA CORPORATION#6-9, HIRANOMACHI 2-CHOME, CHUO-KU#OSAKA-SHI, OSAKA 541-0046 (JP)

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: LU

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20060403

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: CY

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20051207

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PCAR

    Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH)

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: PLFP

    Year of fee payment: 18

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: NL

    Payment date: 20150309

    Year of fee payment: 18

    Ref country code: ES

    Payment date: 20150310

    Year of fee payment: 18

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: CH

    Payment date: 20150414

    Year of fee payment: 18

    Ref country code: DE

    Payment date: 20150331

    Year of fee payment: 18

    Ref country code: GB

    Payment date: 20150401

    Year of fee payment: 18

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: IT

    Payment date: 20150413

    Year of fee payment: 18

    Ref country code: BE

    Payment date: 20150413

    Year of fee payment: 18

    Ref country code: FR

    Payment date: 20150408

    Year of fee payment: 18

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: BE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20160430

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: R119

    Ref document number: 69832709

    Country of ref document: DE

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PL

    REG Reference to a national code

    Ref country code: NL

    Ref legal event code: MM

    Effective date: 20160501

    GBPC Gb: european patent ceased through non-payment of renewal fee

    Effective date: 20160403

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: ST

    Effective date: 20161230

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: CH

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20160430

    Ref country code: NL

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20160501

    Ref country code: FR

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20160502

    Ref country code: LI

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20160430

    Ref country code: GB

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20160403

    Ref country code: DE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20161101

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: IT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20160403

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: ES

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20160404

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FD2A

    Effective date: 20180626